Benefits
Studied in People With Age-Related Macular Degeneration (AMD)
Four small studies gave generic saffron at 20 to 30 mg a day to people already diagnosed with AMD. The largest, a placebo-controlled crossover trial in 100 people over 3 months, found best-corrected visual acuity improved by an average of 0.69 letters on an eye chart, which is less than one letter. A 60-person trial at 30 mg a day found no significant change on OCT scans in dry AMD (p=0.282), and in wet AMD the retinal function gains were no longer significant at the 6-month endpoint (p=0.213). The other two studies reported improved focal ERG flicker sensitivity, but neither had a control group, so those changes cannot be confidently credited to saffron. None of these studies used AffronEYE.
Longer-Term Use: Uncontrolled Study Only
The only longer-term data among the cited studies is an open-label follow-up of 29 people with early AMD who took 20 mg a day of generic saffron for about 14 months. Focal ERG measures of central retinal function stayed improved over that period, but there was no placebo group, so the changes cannot be confidently credited to saffron, and the authors acknowledged that the design undermines causal attribution. No long-term study of AffronEYE itself is cited here.
Antioxidant Activity in the Retina (Laboratory Evidence)
Laboratory research suggests crocins act as antioxidants and may reach retinal tissue. None of the four cited human studies measured macular pigment, blue light damage, or whether AMD progressed more slowly, so this is a proposed mechanism rather than a demonstrated effect in people.
Absorption Speed (Manufacturer Claim)
The manufacturer reports that crocin blood levels peak about 1.5 hours after taking AffronEYE. None of the four studies cited on this page measured absorption, and faster absorption has not been shown to produce any better outcome for vision.
Glaucoma: Animal Research Only
An animal study has been reported in this area, but it is not among the references on this page, and no human trial of saffron for glaucoma is cited here. Animal results do not show what a supplement does in people, and no supplement can prevent glaucoma.
Use Alongside AREDS2 Formulas
In the 100-person crossover trial, some participants were already taking AREDS-type supplements alongside saffron. No cited study has compared saffron head to head with AREDS2, and saffron is not a substitute for it. Anyone with a diagnosed eye condition should make supplement decisions with an eye doctor.
Mechanism of action
Crocin Macular Antioxidant Activity
Crocins are water-soluble carotenoid glycosides — unique among carotenoids for water solubility (lutein/zeaxanthin are lipid-soluble). Laboratory and animal work suggests crocins can reach retinal tissue and act as antioxidants there. None of this was measured in the human studies cited on this page.
Blood Flow / Microcirculation Enhancement
Crocins have been proposed to affect blood flow in the small vessels of the retina. No study cited on this page measured retinal blood flow, so this remains a hypothesis rather than a shown effect.
Photoreceptor Protection
Laboratory studies suggest crocins may shield photoreceptor cells from oxidative damage. This is a proposed explanation for the small retinal function changes seen in the AMD studies, not something those studies tested.
Anti-Inflammatory / Neuroprotective
Saffron compounds have shown anti-inflammatory and nerve-protecting activity in laboratory and animal research. Whether this happens in the human eye was not tested in any of the studies cited here.
Faster Bioavailability vs Other Carotenoids
Because crocins dissolve in water, they are absorbed differently from fat-soluble carotenoids such as lutein. No study cited here compared absorption between them or measured how much reaches the retina.
Clinical trials
Randomized, double-blind, placebo-controlled crossover trial in 100 people, using 20 mg a day of generic (not branded) saffron for 3 months (Broadhead 2019, PMID 30343354).
100 adults already diagnosed with mild or moderate AMD, some of whom were also taking AREDS-type supplements.
Best-corrected visual acuity improved by an average of 0.69 letters on an eye chart (p=0.001) and multifocal ERG timing by 0.17 milliseconds (p=0.04). Both differences are statistically significant but very small, and a change of less than one letter is not one a person would be expected to notice. The authors describe the size of the benefit as modest. AffronEYE was not used in this trial.
Open-label follow-up of 29 people with early AMD taking 20 mg a day of generic saffron for about 14 months, with no placebo group (Piccardi 2012, PMID 22852021).
29 adults with early AMD.
Retinal function measures stayed improved over the follow-up and no safety problems were reported. Because everyone knew they were taking saffron and there was no comparison group, the changes cannot be confidently attributed to the supplement. This does not establish that saffron manages AMD.